A photo of Mayur Sarangdhar.

Member, Division of Oncology

Assistant Professor, UC Department of PediatricsUC Department of Biomedical Informatics


Biography & Affiliation


Dr. Sarangdhar is a bioinformatics-trained computational scientist interested in unraveling the underlying causes and mechanisms of drug toxicity. His research focuses on integrating high-dimensional computational approaches with systems biology knowledgebase to accelerate the discovery of novel drug-toxicity relationships buried in heterogeneous big data. Dr. Sarangdhar developed a novel platform, AERSMine, to mine the clinical responses of millions of patients to all FDA-approved drugs in order to identify unexpected clinical harm, benefits and alternative treatment choices for individual patients. AERSMine provides an insight into sub-population-specific differential therapeutic risks, and creates an avenue to improve our understanding of the molecular basis of adverse drug reactions.

Dr. Sarangdhar is also a member of the Children’s Oncology Group and is leading the effort to delineate differential treatment- and age-specific toxicity profiles within pediatric and young adult cancer patients across multiple studies and disease groups. He is designing computational approaches that facilitate effective analysis of large-scale datasets including clinical trials so we can identify a) the true regimen-specific differential risks associated with chemotherapy, b) the underlying genetic factors that drive exacerbation of toxicities, and c) recognize effective personalized therapeutic strategies for individuals at highest risk of complications.

His group is developing integrative analytical approaches that combine machine learning techniques with toxicity data, genotype-phenotype relationships, and gene-regulatory mechanisms, to help facilitate modelling novel and effective therapeutics.

Research Interests

Systems pharmacology; developmental pharmacology; cardio-oncology; drug-induced toxicities; drug repositioning

Academic Affiliation

Assistant Professor, UC Department of PediatricsUC Department of Biomedical Informatics

Research Divisions

Oncology, Biomedical Informatics

Blog Posts

AERSMine Helps Investigators Dig Into Massive FDA Database

Tools for Science

AERSMine Helps Investigators Dig Into Massive FDA Database

Mayur Sarangdhar, PhD, Anil Goud Jegga, DVM, MRes ...6/29/2019


BE: Computer Science, University of Mumbai, Mumbai, India, 2004.

MRes: Computer Science and Artificial Intelligence, University of Sussex, UK, 2005.

PhD: Computer Science, University of Hull, UK, 2013.

Post-doctoral: Cincinnati Children's Hospital Medical Center, 2015.


Selected Publication

Glucagon-like peptide-1 receptor agonists are not associated with retinal adverse events in the FDA Adverse Event Reporting System. Fadini, GP; Sarangdhar, M; Avogaro, A. BMJ Open Diabetes Research and Care. 2018; 6.

Pharmacovigilance Evaluation of the Association Between DPP-4 Inhibitors and Heart Failure: Stimulated Reporting and Moderation by Drug Interactions. Fadini, GP; Sarangdhar, M; Avogaro, A. Diabetes Therapy. 2018; 9:851-861.

Dipeptidyl peptidase-4 inhibitors moderate the risk of genitourinary tract infections associated with sodium-glucose co-transporter-2 inhibitors. Fadini, GP; Bonora, BM; Mayur, S; Rigato, M; Avogaro, A. Diabetes, Obesity and Metabolism. 2018; 20:740-744.

Data mining differential clinical outcomes associated with drug regimens using adverse event reporting data. Sarangdhar, M; Tabar, S; Schmidt, C; Kushwaha, A; Shah, K; Dahlquist, JE; Jegga, AG; Aronow, BJ. Nature Biotechnology. 2016; 34:697-700.

Using Systems Biology-based Analysis Approaches to Identify Mechanistically Significant Adverse Drug Reactions: Pulmonary Complications from Combined Use of Anti-TNFα Agents and Corticosteroids. Sarangdhar, M; Kushwaha, A; Dahlquist, J; Jegga, A; Aronow, B. AMIA Joint Summits on Translational Science proceedings AMIA Summit on Translational Science. 2013; 2013:151-155.

Therapeutic Opportunities for Intestinal Angioectasia- Targeting PPARγ and Oxidative Stress. Sarangdhar, M; Yacyshyn, MB; Gruenzel, AR; Engevik, MA; Harris, NL; Aronow, BJ; Yacyshyn, BR. Clinical and Translational Science. 2021; 14:518-528.

Modeling Effective AML Therapies - Comparative Anti-Leukemic Synergy of BCL2 and MCL1 Inhibition Combined and with Chemotherapy. O'Brien, E; VanCauwenbergh, B; Alexander, J; Basu, M; Wunderlich, M; Sarangdhar, M; Mizukawa, B; Perentesis, JP. Blood. 2019; 134:3370-3370.

Pharmacovigilance assessment of the association between Fournier's gangrene and other severe genital adverse events with SGLT-2 inhibitors. Fadini, GP; Sarangdhar, M; De Ponti, F; Avogaro, A; Raschi, E. BMJ Open Diabetes Research and Care. 2019; 7.

Rheumatic and musculoskeletal adverse events with immune checkpoint inhibitors: Data from the United States Food and Drug Administration adverse event reporting system. Pundole, XN; Sarangdhar, M; Suarez-Almazor, ME. 2019; 2.

Network analyses of biomedical and genomic Big Data. Sarangdhar, M; Gudivada, RC; Shrestha, RB; Wang, Y; Jegga, AG. Big Data of Complex Networks. 2016.